Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: generationbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | Outperform → Market Perform | TD Cowen | |
| 11/8/2022 | $9.00 | Buy | Canaccord Genuity |
| 12/15/2021 | $40.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $50.00 → $27.00 | Buy | Needham |
| 12/14/2021 | Outperform → Mkt Perform | William Blair |
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
EFFECT - Generation Bio Co. (0001733294) (Filer)
S-3 - Generation Bio Co. (0001733294) (Filer)
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
ARS - Generation Bio Co. (0001733294) (Filer)
TD Cowen downgraded Generation Bio from Outperform to Market Perform
Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00
JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously
Needham reiterated coverage of Generation Bio with a rating of Buy and set a new price target of $27.00 from $50.00 previously
William Blair downgraded Generation Bio from Outperform to Mkt Perform
JMP Securities initiated coverage of Generation Bio with a rating of Mkt Outperform and set a new price target of $40.00
William Blair initiated coverage of Generation Bio with a rating of Outperform and set a new price target of $45.00
Needham & Company LLC initiated coverage of Generation Bio with a rating of Buy and set a new price target of $50.00
William Blair initiated coverage of Generation Bio with a rating of Outperform
William Blair initiated coverage of Generation Bio with a rating of Outperform and set a new price target of $45.00
Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2024 financial results. "There is immense potential for a new class of redosable, selectively targeted in vivo genetic medicines to fulfill the needs of people living with diseases that remain unaddressed by existing treatment options," said Geoff
New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress. The company presented data showing that a single IV dose of its ctLNP delivered mRNA encoding a reporter protein to a majority of circulating T cells in non-human primates (NHPs). In the
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is innovating non-viral genetic medicines
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2024 financial results. "We continue to apply our proprietary cell-targeted LNP delivery system to develop in vivo genetic medicines for T cells, hematopoietic stem cells and hepatocytes," said Geoff McDonough, chief executive officer of Generation Bio. "We believe our delivery platform has the potential to create uniquely differentiated in vivo therapeutics that are redosable, delivered at point-of-care, and scalable at low cost, thereby addressing chal
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th, 2024 at 2:30 p.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is innovating non-viral genetic medicines to
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the virtual 2024 TD Cowen Genetic Medicines & RNA Summit on Friday, June 21st, 2024 at 1:50 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is innovating non-viral genetic medicine
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis - Cash balance of $233.9 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported additional data on its cell-targeted lipid nanoparticle (ctLNP) platform presented at the Ame
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA performance through process development and the identification of novel structural elements Data on cell-targeted LNP (ctLNP) in vivo delivery of therapeutic transgenes to T cells to be discussed in an oral presentation on Saturday, May 11 CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and c
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, MD. "We are delighted to have a robust presence at this year's ASGCT meeting and showcase some of the innovative technical work underpinning the breakthrough
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is innovating non-viral genetic medicines to provide d
Gainers Delcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out today. Harrow (NASDAQ:HROW) stock rose 32.64% to $16.01. The company's market cap stands at $566.4 million. As per the press release, Q1 earnings came out yesterday. ProKidney (NASDAQ:PROK) shares moved upwards by 26.29% to $3.89. The company's market cap stands at $248.6 million. As per the news, the Q1 earnings report came out 2 days ago. Sunshine Biopharma (NASDAQ:SBFM) stock rose 25.14% to $1.09. The market value of their outstanding shares is at $1.0 million. Pacific Biosciences (NASDAQ:
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $10 price target.
Wedbush analyst David Nierengarten reiterates Generation Bio (NASDAQ:GBIO) with a Outperform and maintains $5 price target.
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.41) by 173.17 percent. The company reported quarterly sales of $4.059 million which beat the analyst consensus estimate of $1.920 million by 111.41 percent.
Data included in the posters describe iqDNA as a modified, structured, partially single-stranded DNA that evades innate immunity while remaining transcriptionally active in the cell. In mouse studies, the immune profile of iqDNA is consistent with avoidance of key innate immune pathways such as cGAS-STING, which is known to have a significantly lower binding affinity for single-stranded DNA than double-stranded DNA. Given the non-immunogenic nature of iqDNA, Generation Bio believes it can now create novel therapies with a wide therapeutic index, which has been a major challenge to the development of in vivo DNA-based genetic medicines.
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $10 price target.
Wedbush analyst David Nierengarten reiterates Generation Bio (NASDAQ:GBIO) with a Outperform and maintains $5 price target.
Needham analyst Gil Blum maintains Generation Bio (NASDAQ:GBIO) with a Buy and lowers the price target from $14 to $10.
Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. "We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "This quarter, process development and scaling of rapid enzymatic synthesis (RES) for prod
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations. She is currently the Chief Operating Officer of Rubius Therapeutics, where she oversees Corporate Strategy, Communications, Quality, Technical Development and Operations. Prior to joining Rubius, Appelhans held multiple executive-level positions at Novartis, including Global
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. Ron Cooper is a global biopharmaceutical executive who currently serves as president, chief executive officer and board member of Albireo Pharma, Inc., a position he has held since June 2015. He has successfully matured Albireo Pharma, Inc. to a clinical-stage public company on the verge of its first drug approval. Prior to joining Albireo Pharma, Inc., Cooper had a 25-year career at Bristol Myers Squibb, d